Hongcan Liu

Dr. Hongcan Liu


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Journal of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
YWYunxiu Wang
Yunxiu Wang
BWBaiye Wang
Baiye Wang
LSLanhui She
Lanhui She
JWJijuan Wang
Jijuan Wang
YCYingting Chen
Yingting Chen
HLHongcan Liu
Hongcan Liu
Objectives: To investigate the influence of preservation methods and processes on the plasma interleukin-6 (IL-6) stability. Methods: Lithium-heparin plasma was collected from female patients: 32 female patients with invasive breast neoplasms and 20 healthy females. Each sample was divided into three tubes. Samples were stored at different temperatures or at different times. The concentration of IL-6 was detected. Results: IL-6 levels in patients were not altered significantly compared to the control group after storage at 4 °C or 25 °C for 12 h. However, IL-6 levels were significantly higher compared to controls (p<0.05) after storage at 25 °C for 48 h. IL-6 levels in patients with breast neoplasms were significantly higher compared to the control group (p<0.05) when stored at 4 °C after 12 h. IL-6 levels in patients with breast neoplasm increased more than 10-folds compared to the control group after only 2 h storage at 25 °C. Conclusions: Concentrations of IL-6 in breast neoplasms samples significantly change under different storage conditions. Pretreatment needs to be standardized for blood sample handling procedure. Comparison of different storage conditions of IL-6 levels may not be reliable.

15 April 2021 in Frontiers in Pharmacology
Verified
Journal Article
Open access
HLHongcan Liu
Hongcan Liu
ZWzemin wan
zemin wan
LSLanhui She
Lanhui She
YZYajuan Zhu
Yajuan Zhu
ZCZhiliang Cai
Zhiliang Cai
XHXianzhang Huang
Xianzhang Huang
Background/Aims: Emergence of tyrosine-methionine-aspartate-aspartate (YMDD) motif in reverse transcriptase is a serious problem in chronic hepatitis B(CHB) patients after Lamivudine (LAM) therapy. However, the relationship between inflammation pharmacological reaction and YMDD mutational patterns of CHB has not been well-characterized. The aim of this study was to investigate the inflammation pharmacological reaction and different YMDD mutants patterns of CHB patients.Methods: We investigated the inflammation pharmacological reaction and YMDD mutational patterns through biochemical, serological and virological detection among 83 CHB patients, including 25 YMDD mutants, 25 under detection, and 33 control patients without YMDD mutants.Results: Prevalence of YMDD mutation patterns is different. Among 25 YMDD mutants patients, YIDD was the dominant mutation (72%), followed YVDD (16%) and the hybrid YIDD + YVDD (12%). The time course during the YMDD mutations was also different. 52.4% patients developed the mutation less than 12 months after the LAM therapy. Serum hepatitis B virus (HBV) DNA level in patients with YMDD mutants were significantly higher than that in control and negative groups. Serum HbsAg and HbeAg in patients with YMDD mutants were also higher than those in control and negative groups, despite no significant difference was found forserum HbeAb. ALT and AST levels were also significantly higher in mutants group.Conclusions: Illuminating inflammation pharmacological reaction and YMDD mutational patterns of CHB during pathological process may have implications for future therapy in YMDD mutation patients. This may have impact on the choice of treatment strategies for lamivudine-resistant HBV.